MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology announced new data from its Phase 2 THIO-101 clinical trial, showing promising results for the drug THIO when combined with cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC) patients who have failed 2 or more standard-of-care therapies.
The trial reports a favorable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85%, significantly surpassing the standard-of-care DCR of 25-35%. Median progression-free survival (PFS) for patients treated with THIO was 5.5 months, with a median survival follow-up time of 9.1 months.
Furthermore, 65% of patients crossed the 5.8-month overall survival (OS) threshold, and 85% crossed the 2.5-month PFS threshold. The data was presented at the ASCO 2024 Annual Meeting.
Full enrollment for the trial was completed ahead of schedule on February 19, 2024, and the company anticipates full efficacy data by the second half of the year. The treatment has been generally well tolerated by patients.
MAIA Biotechnology (NYSE American: MAIA), a clinical stage company specializing in telomere-targeting immunotherapies for cancer, will participate in the BIO International Convention from June 3-6, 2024, in San Diego. The event gathers over 20,000 biotech industry leaders globally. CEO Vlad Vitoc, M.D., will present findings from the Phase 2 THIO-101 clinical trial, which assesses the efficacy of THIO, a telomere-targeting agent, combined with the immune checkpoint inhibitor cemiplimab (Libtayo®) in treating advanced non-small cell lung cancer. This trial could mark the first completion of a telomere-targeting agent study in cancer treatment. Dr. Vitoc’s presentation is set for June 5 at 11:30 a.m. PDT in the San Diego Convention Center. The MAIA team will also hold meetings with key industry stakeholders during the event.
MAIA Biotechnology announced that an abstract from its Phase 2 THIO-101 clinical trial has been accepted for a poster presentation at the ASCO 2024 Annual Meeting. The trial involves the investigation of THIO, a telomere-targeting agent, sequenced with cemiplimab in treating advanced non-small cell lung cancer (NSCLC). The poster presentation is scheduled for June 3, 2024, from 1:30 pm to 4:30 pm CST in Chicago. MAIA emphasizes the uniqueness of THIO as the first cancer treatment of its kind in clinical development. Additional details will be accessible online on the ASCO website a week before the conference and on MAIA's website on the day of the presentation.
MAIA Biotechnology, Inc. announced that director Adelina Louie purchased 19,665 shares and warrants in a private placement of common stock, showing confidence in the company's mission of developing cancer immunotherapies. Louie, a top MAIA investor, has a background in finance and banking, with 30 years of experience at HSBC Group.
MAIA Biotechnology, Inc. announced that independent director Stan V. Smith, Ph.D., purchased 147,492 shares and warrants for 147,492 shares of MAIA's common stock as part of a recent private placement. MAIA entered into agreements for the purchase of 494,096 shares at $2.034 per share, raising approximately $1.0 million. The securities were issued pursuant to the Company's 2021 Equity Incentive Plan. Dr. Smith's purchase demonstrates support for MAIA's innovative cancer therapy approach.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.